BEDAQUILINE (TMC207, R207910)

Description: Bedaquiline (formerly also known as TMC207 and R207910; sold under the brand name Sirturo) is an orally bioavailable medication used to treat active tuberculosis. It is structurally a diarylquinoline that inhibits mycobacterial ATP synthase. Bedaquiline is specifically used to treat multi-drug-resistant tuberculosis (MDR-TB) when other treatments cannot be used. It should be used along with at least three other medications for tuberculosis. Bedaquiline was approved for medical use in the United States in 2012. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. The cost for six months is approximately $900 USD in low income countries, $3, 000 USD in middle income countries, and $30, 000 USD in high income countries.

References: Ann Pharmacother. 2014 Jan; 48(1):107-15; Antimicrob Agents Chemother. 2017 Apr 24; 61(5). pii: e02627-16.

Related CAS#: 845533-86-0 (fumarate) 843663-66-1 (free base) 54655-80-8 (racemate)